TY - JOUR
T1 - Epidemiology and Burden of Sleep Disturbances in Atopic Dermatitis in US Adults
AU - Silverberg, Jonathan Ian
AU - Chiesa-Fuxench, Zelma
AU - Margolis, David
AU - Boguniewicz, Mark
AU - Fonacier, Luz
AU - Grayson, Mitchell
AU - Simpson, Eric
AU - Ong, Peck
N1 - Funding Information:
J.I.S. served as a consultant and/or advisory board member for Abbvie, Asana, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi, Realm, and Roivant receiving honoraria; speaker for Regeneron-Sanofi; and received research grants from GlaxoSmithKline and Regeneron-Sanofi. J.I.S. is supported by the Dermatology Foundation. J.M.G. served as a consultant to BMS, Boehringer Ingelheim, GSK, Janssen Biologics, Menlo Therapeutics, Novartis Corp, Regeneron, Dr Reddy's Laboratories, UCB (DSMB), Sanofi, and Pfizer, Inc, from which he received honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer, Inc; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Ortho Dermatologics. J.M.G. is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma. J.M.G. is a deputy editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology. Z.C.C.F. has served as a consultant to the National Eczema Association, Asthma and Allergy Foundation, and Abbvie, from which she received honoraria, and receives or has received research grants (to the Trustees of the University of Pennsylvania) from Regeneron, Sanofi, Tioga and Vanda Pharmaceuticals, Realm Therapeutics, and Leo for work in atopic dermatitis and has received payment for continuing medical education work related to atopic dermatitis that was supported indirectly by Regeneron and/or Sanofi. D.M. is the chair of the data monitoring committee for many Sanofi clinical trials of dupilamab and, with respect to atopic dermatitis, has received independent research funding to his institution from the National Institute of Health and Valeant. M.B. has received research funding from Anacor and Regeneron and consulted for Regeneron, Sanofi Genzyme, and Pfizer. L.F. has served as a consultant to Regeneron, Pfizer, Lilly, and Abbvie, from which she received honoraria, and received research and educational grants from Regeneron, Genentech, Baxter, and Pfizer. M.G. is a board member of Allergy and Asthma Foundation of America and chair for the Allergy and Asthma Foundation of America Medical Scientific Council and has served as a consultant to AstraZeneca, GlaxoSmithKline, Aimmune, DBV, and Genzyme. E.S. has served as a consultant and/or advisory board member for Regeneron-Sanofi. P.O. is a coinvestigator of Atopic Dermatitis Research Network, has consulted for Pfizer and Theravance, and has received research funding from Regeneron. Atopic Dermatitis in America Study is an independent research project of the Asthma and Allergy Foundation of America in partnership with the National Eczema Association and sponsored by Sanofi Genzyme and Regeneron.
Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Background The relationship between atopic dermatitis (AD) severity, sleep disturbance (SD), and health-related outcomes is not fully elucidated. Objective The aim of the study was to determine the prevalence of SD in adult AD and its relationship with AD severity and health outcomes among the US population. Methods A cross-sectional, US population-based survey study of 2893 adults was performed. Results Among adults meeting the UK Diagnostic Criteria for AD, 255 (40.7%) reported 1 or more, 67 (11.1%) reported 3 to 4, and 57 (9.5%) reported 5 to 7 nights of SD in the past week; 475 (79.7%) reported at least some trouble sleeping in the past 3 days. Moderate and severe Patient-Oriented Scoring AD, Patient-Oriented Eczema Measure, and Numeric Rating Scale-itch and Numeric Rating Scale-skin pain scores were associated with more severe SD compared with those without AD. More frequent and severe SDs were associated with higher Dermatology Life Quality Index, lower 12-item Short-Form Health Survey, and higher Hospital Anxiety and Depression Scale (HADS) scores. Significant mediation by SD severity was observed between Patient-Oriented Eczema Measure and Numeric Rating Scale-itch with Dermatology Life Quality Index, 12-item Short-Form Health Survey physical and mental component scores, HADS-anxiety and HADS-depression scores, diagnosed anxiety, and heart disease. Conclusions Atopic dermatitis and AD severity are associated with SDs. Sleep disturbances considerably impact quality of life and other health outcomes in adults with AD.
AB - Background The relationship between atopic dermatitis (AD) severity, sleep disturbance (SD), and health-related outcomes is not fully elucidated. Objective The aim of the study was to determine the prevalence of SD in adult AD and its relationship with AD severity and health outcomes among the US population. Methods A cross-sectional, US population-based survey study of 2893 adults was performed. Results Among adults meeting the UK Diagnostic Criteria for AD, 255 (40.7%) reported 1 or more, 67 (11.1%) reported 3 to 4, and 57 (9.5%) reported 5 to 7 nights of SD in the past week; 475 (79.7%) reported at least some trouble sleeping in the past 3 days. Moderate and severe Patient-Oriented Scoring AD, Patient-Oriented Eczema Measure, and Numeric Rating Scale-itch and Numeric Rating Scale-skin pain scores were associated with more severe SD compared with those without AD. More frequent and severe SDs were associated with higher Dermatology Life Quality Index, lower 12-item Short-Form Health Survey, and higher Hospital Anxiety and Depression Scale (HADS) scores. Significant mediation by SD severity was observed between Patient-Oriented Eczema Measure and Numeric Rating Scale-itch with Dermatology Life Quality Index, 12-item Short-Form Health Survey physical and mental component scores, HADS-anxiety and HADS-depression scores, diagnosed anxiety, and heart disease. Conclusions Atopic dermatitis and AD severity are associated with SDs. Sleep disturbances considerably impact quality of life and other health outcomes in adults with AD.
KW - Abbreviations
KW - AD = atopic dermatitis
KW - aOR = adjusted odds ratio
KW - CI = confidence interval
KW - DLQI = Dermatology Life Quality Index
KW - HADS-A = Hospital Anxiety and Depression Scale-anxiety
KW - HADS-D = Hospital Anxiety and Depression Scale-depression
KW - HRQoL = health-related quality of life
KW - HS = high school
KW - MCS = mental component score
KW - NRS = Numerical Rating Scale
KW - PCS = physical component score
KW - PO-SCORAD = Patient-Oriented Scoring Atopic Dermatitis
KW - POEM = Patient-Oriented Eczema Measure
KW - SD = sleep disturbance
KW - SE = standard error
KW - SF-12 = 12-item Short-Form Health Survey
KW - UKWP = UK Working Party
UR - http://www.scopus.com/inward/record.url?scp=85142403708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142403708&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000731
DO - 10.1097/DER.0000000000000731
M3 - Article
C2 - 33675326
AN - SCOPUS:85142403708
SN - 1710-3568
VL - 33
SP - S104-S113
JO - Dermatitis : contact, atopic, occupational, drug
JF - Dermatitis : contact, atopic, occupational, drug
IS - 6
ER -